Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
WO2021014386A1
Selective estrogen receptor degrader
WO2019229719A1
An injection device
EP3641734A2
Abuse deterrent oral solid dosage form
WO2018185788A1
Ophthalmic solution of bimatoprost
WO2018167802A1
Novel amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide
AU2018235447A1
Novel amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[N'-(2chloro-6-methylbenzoyl)hydrazinocarbonyl]-2-methyl-phenylethynyl}-pyridin-2-yl)amide
WO2018138739A1
Novel antiestrogenic heterocyclic compounds
WO2018002958A1
Novel hydrazide containing compounds as btk inhibitors
KR20190015257A
Treatment of Parkinson's Disease
WO2017168454A2
Novel compounds as btk inhibitors
EP3416608A1
A portable device for cutting a capsule
WO2017134685A2
Novel hydrazino compounds as btk inhibitors
CA3001958A1
Novel heterocyclic antiestrogens
US2018311159A1
Ophthalmic solution of difluprednate
US2019008772A1
Drug loaded nanoresin particles
AU2016280873A1
Long acting liraglutide compositions
KR20180011772A
The novel amido heteroaryl aroyl hydrazide ethyne
AU2016210812A1
Crystalline form of S-(4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl)6alpha, 9alpha -difluoro-17alpha,-(furan-2-yl)carbonyloxy-11beta-hydroxy-16alpha-methy1-3-oxoandrosta-1,4-diene-17beta-carbothioate
